🇺🇸 FDA

Intelligence · Clinical Pipeline

Infectious disease R&D Pipeline

Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Programs
1,126

Quick answer

Infectious disease: NovaPharmaNews indexes 1,126 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Top sponsors

Page 2 of 24

  1. CEFTRIAXONE , TEMOCILLIN , Negaban 2 g poudre pour solution injectable/pour perfusion

    Pari Pharma GmbH

    Neisseria gonorrhoeae Infections

    phase 3 small molecule active

    1 trial
  2. COBI

    Gilead Sciences Ireland UC

    HIV

    phase 3 small molecule completed

    1 trial
  3. COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    1 trial
  4. COVID-19 Vaccine,Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    1 trial
  5. CP101

    Finch Therapeutics Group

    Recurrent C. Difficile Infection

    phase 3 mab terminated

    1 trial
  6. CPI-006 2 mg/kg + SOC

    Corvus Pharmaceuticals

    Covid-19

    phase 3 small molecule terminated

    1 trial
  7. Cannabidiol, pharmaceutically produced with < 5 ppm THC

    Cardiol Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial
  8. Carraguard (PC-515)

    United Therapeutics Europe Ltd

    HIV Infections

    phase 3 small molecule completed

    2 trials
  9. Ceftaroline

    Pfizer

    Community-Acquired Bacterial Pneumonia

    phase 3 small molecule completed

    1 trial
  10. Ceftazidime - Avibactam ( CAZ-AVI)

    Pfizer

    Complicated Urinary Tract Infection

    phase 3 small molecule completed

    1 trial
  11. Ceftazidime-avibactam

    Pfizer

    Complicated Intra-abdominal Infection

    phase 3 small molecule completed

    1 trial
  12. Ceftriaxone

    Adaptive Biotechnologies Corp

    Community-acquired Pneumonia, Influenza, COVID-19

    phase 3 small molecule active

    1 trial
  13. Cellulose Sulfate gel (6%)

    United Therapeutics Europe Ltd

    HIV Infection

    phase 3 small molecule terminated

    1 trial
  14. Cervarix™

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial
  15. Cetirizine

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 3 small molecule terminated

    1 trial
  16. Cholecalciferol (Vitamin D/Vigantol oil)

    United Therapeutics Europe Ltd

    Respiratory Tract Infections

    phase 3 other completed

    1 trial
  17. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial
  18. Co-Trimoxazole 960Mg Dispersible Tablet

    United Therapeutics Europe Ltd

    Spontaneous Bacterial Peritonitis

    phase 3 small molecule active

    1 trial
  19. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial
  20. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV Infection

    phase 3 small molecule active

    1 trial
  21. DTG + 3TC

    ViiV Healthcare B.V.

    HIV Infections

    phase 3 small molecule completed

    1 trial
  22. DUOFAG, Chlorid sodný B. Braun 0,9 % infuzní roztok

    Lacuna Pharma Pty Ltd

    Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.

    phase 3 small molecule active

    1 trial
  23. Daclatasvir

    Bristol-Myers Squibb

    Hepatitis C Virus Infection

    phase 3 small molecule completed

    2 trials
  24. Descovy or Truvada

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial
  25. Directly administered antiretroviral therapy (DAART)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 other completed

    2 trials
  26. Dociparstat sodium

    Jazz Pharmaceuticals Ireland Limited

    Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule terminated

    1 trial
  27. Dolutegravir/abacavir/lamivudine FDC

    ViiV Healthcare B.V.

    Infection, Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial
  28. Dovato 50 mg/300 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    ViiV Healthcare Pty Ltd

    Human immunodeficiency virus (HIV)

    phase 3 small molecule active

    1 trial
  29. Dovato 50 mg/300 mg film-coated tablets, Dovato 50 mg/300 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Vocabria 400 mg prolonged-release suspension for injection, Vocabria 600 mg prolonged-release suspension for injection

    ViiV Healthcare Pty Ltd

    HIV-1 infection

    phase 3 small molecule active

    1 trial
  30. Dovato 50 mg/300 mg film-coated tablets, Truvada 200 mg/245 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets, Combivir 150 mg/300 mg film-coated tablets, Epivir 300 mg film-coated tablets, Ziagen 300 mg film-coated tablets, Retrovir 250 mg capsules, hard, Kivexa 600 mg/300 mg film-coated tablets, Triumeq 50 mg/600 mg/300 mg film-coated tablets

    Fondazione Telethon ETS

    HIV-infected

    phase 3 small molecule active

    1 trial
  31. Doxycycline Sandoz 100 mg tabletten, Doxycycline EG 200 mg Tabletten

    The George Institute

    Sexually Transmitted Infections

    phase 3 small molecule active

    1 trial
  32. Drotrecogin alfa (activated)

    Eli Lilly and Company

    Sepsis

    phase 3 small molecule completed

    1 trial
  33. Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment

    United Therapeutics Europe Ltd

    COVID19

    phase 3 small molecule active

    1 trial
  34. EMB-Fatol® 100 mg, Tabletten, The placebo for Amikacin Liposome for Inhalation Suspension drug product is a white translucent suspension consisting of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, which are dispersed in 1.5% (w/w) sodium chloride solution. The placebo is filled into the same container closure system of the drug product, Azithromycin-ratiopharm 250mg Filmtabletten, Azithromycin STADA® 250 mg Filmtabletten, Azithromycin AL 250 mg Filmtabletten, Azitromicina Teva 250 mg comprimidos re

    Insmed Limited

    "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"

    phase 3 small molecule active

    1 trial
  35. EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, Placebo to BIK/FTC/TAF, islatravir, ulonivirine, MK-8591B, Placebo to 8591B

    Merck Sharp and Dohme

    HIV

    phase 3 small molecule active

    1 trial
  36. EVO100

    Evofem Biosciences

    Chlamydia Trachomatis Infection

    phase 3 small molecule completed

    1 trial
  37. Eltrombopag

    GlaxoSmithKline

    Non-alcoholic Steatohepatitis

    phase 3 small molecule terminated

    1 trial
  38. Entecavir

    Bristol-Myers Squibb

    Hepatitis B, Chronic

    phase 3 small molecule completed

    1 trial
  39. Entecavir

    Hoffmann-La Roche

    Pediatric Immuno-Tolerant Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial
  40. Ertapenem

    Iterum Therapeutics plc

    Intra Abdominal Infections

    phase 3 small molecule completed

    1 trial
  41. Erythromycin

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial
  42. Evolocumab

    COLLEGIUM PHARMACEUTICAL, INC

    Sars-CoV-2 Infection

    phase 3 small molecule completed

    1 trial
  43. FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%

    The George Institute

    Patients with hip or knee infections

    phase 3 small molecule active

    1 trial
  44. Flomoxef

    Takeda

    Urinary Tract Infection

    phase 3 small molecule terminated

    1 trial
  45. Formosa 1-Breath Free (NRICM101)

    Hospital Authority, Hong Kong

    Influenza Viral Infections

    phase 3 small molecule active

    1 trial
  46. Fosmanogepix, POSACONAZOLE , AMPHOTERICIN B , CASPOFUNGIN , ISAVUCONAZOLE , MICAFUNGIN , TERBINAFINE , VORICONAZOLE , ANIDULAFUNGIN , -, Fosmanogepix

    Lacuna Pharma Pty Ltd

    Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds

    phase 3 small molecule active

    1 trial
  47. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Covid19

    phase 3 small molecule completed

    1 trial
  48. Furazidin, vaginal tablets, 5mg, Dalacin 20 mg/g hüvelykrém

    Lacuna Pharma Pty Ltd

    Bacterial vaginosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many infectious disease pipeline programs are tracked?

1,126 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs